资讯

Nasdaq2 年
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance ...
(NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the ...
Seeking Alpha2 年
GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
(EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that its ...
Yahoo Finance1 年
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...
manilatimes6月
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as ...
Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® ...
Seeking Alpha2 年
New GIMOTI Patent Listed in FDA Orange Book
a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its recently ...
Benzinga.com2 年
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
EVOK, a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States ...
Yahoo Finance1 年
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of ...
SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with ...